← All trials
NCT05662527
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2023
- Primary completion
- Jul 31, 2025
- Completion date
- Jul 31, 2028
- First posted
- Dec 22, 2022
- Last posted
- Dec 22, 2022
- Enrollment
- 85
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of CopenhagenLead sponsor
- Region SyddanmarkCollaborator
- Aarhus UniversityCollaborator
- Horsens HospitalCollaborator
- Randers Regional HospitalCollaborator
- University of Southern DenmarkCollaborator
- Aalborg UniversityCollaborator
- University of CopenhagenCollaborator
- University of CopenhagenCollaborator
- University of CopenhagenCollaborator
- University of CopenhagenOverall official - principal investigator
- University of CopenhagenSponsor investigator
- University of CopenhagenStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.